Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29552624 | 0.88 | KMT2A (0.71) | KMT2AHDAC1HDAC2 | |
| SCHEMBL28730479 | 0.88 | KMT2A (0.71) | KMT2AHDAC1HDAC2 | |
| SCHEMBL4785263 | 0.87 | KMT2A (0.70) | KMT2AHTTHDAC1HDAC2LMNA | |
| SCHEMBL23574786 | 0.86 | FOLH1 (0.58) | KMT2AHDAC1HDAC2FOLH1MMP2 | |
| SCHEMBL29400684 | 0.86 | FOLH1 (0.58) | KMT2AHDAC1HDAC2FOLH1MMP2 | |
| SCHEMBL23574788 | 0.86 | FOLH1 (0.58) | KMT2AHDAC1HDAC2FOLH1MMP2 | |
| SCHEMBL119447 | 0.86 | FOLH1 (0.58) | KMT2AHDAC1HDAC2FOLH1MMP2 | |
| SCHEMBL120774 | 0.86 | FOLH1 (0.58) | KMT2AHDAC1HDAC2FOLH1MMP2 | |
| SCHEMBL178815 | 0.83 | FOLH1 (0.62) | KMT2AHDAC1HDAC2FOLH1TGM2 | |
| SCHEMBL8823890 | 0.83 | FOLH1 (0.62) | KMT2AHDAC1HDAC2FOLH1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | ASTELLAS PHARMA INC. (JP) | 2007-06-21 | — | — | US | disclosed |
| CN-1898227-A | As prostaglandin E2Ornithine derivatives as agonists or antagonists | ASTELLAS PHARMA INC (JP) | 2007-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | PTGER4, OXER1, RXFP4 | KMT2A 1128/4885HTT 4290/4885HDAC1 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.